Araris Biotech

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Their linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.
Building tomorrow's antibody-drug conjugates

Get to know Araris Biotech

  • Headquartered in: Zurich, Switzerland

  • Founded in: 2019

  • Sector: Biotechnology, Medtech

  • Investor: Managed Partner Funds

Press enter or esc to cancel